RxDoctor Payments Data

Rebecca Vaughn

Family · Cookeville, TNNPI 1629110176

Payments from drug & device makers

$2,569in general payments, 2019–2025

Across 156 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$705
  • Lilly USA, LLC$366
  • AstraZeneca$337
  • AbbVie$294
  • Boston Scientific$157
  • GSK$148
  • plus $561 from 16 others

What the payments were for

  • Food & beverage$2,569100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,569 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$60,330
Medicare patients
221
Services billed
1,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide12$17,043
EliquisApixaban11$13,625
FarxigaDapagliflozin Propanediol13$12,017
Atorvastatin Calcium98$1,336
Naratriptan Hcl11$803
Levothyroxine Sodium116$675
Omeprazole61$669
Np ThyroidThyroid,pork12$615
Pantoprazole Sodium37$542
Losartan Potassium35$523
Lisinopril103$508
Trazodone Hcl32$482
Albuterol Sulfate HfaAlbuterol Sulfate21$467
Doxycycline Hyclate49$466
Ondansetron OdtOndansetron29$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$366$17,04312 claims
PfizerEliquis$19$13,62511 claims
AstraZenecaFarxiga$337$12,01713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →